奥泽沙星乳膏治疗成人和儿童脓疱疮的疗效与安全性:一项随机临床试验
这项随机双盲溶媒对照试验纳入411例2个月及以上脓疱疮患者,比较1%奥泽沙星乳膏与安慰剂每日两次外用5天的疗效。奥泽沙星5天临床成功率54.4%优于安慰剂37.9%(P=.001),2天微生物学成功率87.2%优于63.9%(P=.002),耐受性良好,无严重不良事件。
要点
- 1%奥泽沙星乳膏每日两次外用5天,临床成功率54.4%优于安慰剂37.9%(P=.001)。
- 治疗2天微生物学成功率87.2%优于安慰剂63.9%(P=.002)。
- 206例中8例出现不良事件,仅1例可能与研究治疗相关,无严重不良事件。
核心结论
- 外用奥泽沙星对2个月及以上脓疱疮患者有效且耐受性良好,应答起效快,临床和微生物学应答优于安慰剂,为脓疱疮治疗提供新选择。
研究设计与样本
- 随机、双盲、溶媒对照临床试验,2014年6月2日至2015年5月30日在6个国家的研究中心入组2个月及以上脓疱疮患者。
- 患者按1:1随机接受外用奥泽沙星或安慰剂对照,共411例接受治疗(男性210例[51.1%],平均[SD]年龄18.6[18.3]岁)。
- 数据基于意向治疗分析,分析时间为2015年7月9日至7月22日。
主要发现
- 治疗5天后临床成功:奥泽沙星组112/206例(54.4%)vs 安慰剂组78/206例(37.9%),P=.001。
- 治疗2天后微生物学成功:奥泽沙星组109/125例(87.2%)vs 安慰剂组76/119例(63.9%),P=.002。
- 奥泽沙星耐受性良好,206例中8例出现不良事件,仅1例可能与研究治疗相关,无严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Ozenoxacin, a novel topical antibacterial agent with potent bactericidal activity against gram-positive bacteria, has been developed as a cream with 1% active drug for the treatment of impetigo, a highly contagious bacterial skin infection. OBJECTIVES: To evaluate the efficacy, safety, and tolerability of ozenoxacin cream, 1%, after 5-day twice-daily topical treatment in patients with impetigo. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, vehicle-controlled clinical trial included patients 2 months or older with impetigo who were enrolled at centers in 6 countries from June 2, 2014, through May 30, 2015. Data were analyzed based on intention to treat from July 9 through July 22, 2015. INTERVENTIONS: Patients were randomized 1:1 to receive topical ozenoxacin or placebo control. MAIN OUTCOMES AND MEASURES: Efficacy was measured using the Skin Infection Rating Scale and microbiological culture. Safety and tolerability were also evaluated. RESULTS: Among the 411 patients who received treatment (210 males [51.1%]; mean [SD] age, 18.6 [18.3] years), ozenoxacin demonstrated superior clinical success compared with placebo, which was evident after 5 days of therapy (112 of 206 [54.4%] vs 78 of 206 [37.9%]; P = .001). Ozenoxacin also demonstrated superior microbiological success compared with placebo after 2 days of therapy (109 of 125 [87.2%] vs 76 of 119 [63.9%]; P = .002). Ozenoxacin was well tolerated, with 8 of 206 patients experiencing adverse effects, with only 1 of these potentially related to the study treatment; none were serious. CONCLUSIONS AND RELEVANCE: Topical ozenoxacin is effective and well tolerated in the treatment of impetigo in patients 2 months and older. This effect is demonstrated by rapid onset of response and superior clinical and microbiological response compared with placebo. Topical ozenoxacin represents a novel option for the treatment of impetigo. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02090764.
引用
- Rosen T, Albareda N, Rosenberg N, et al. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA Dermatol. 2018. PMID: 29898217. doi:10.1001/jamadermatol.2018.1103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。